MorphoSys Hits Refresh Button On Pipeline With Constellation Buy
Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty
Executive Summary
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
You may also be interested in...
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
MorphoSys Chooses Incyte As Its Global Tafasitamab Partner
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.